Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks-Reference-Cited by-同舟云学术

Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks

Published:2016-02 Issue:2 Volume:64 Page:301-307
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Feld Jordan J.,Moreno Christophe,Trinh Roger,Tam Edward,Bourgeois Stefan,Horsmans Yves,Elkhashab Magdy,Bernstein David E.,Younes Ziad,Reindollar Robert W.,Larsen Lois,Fu Bo,Howieson Kevin,Polepally Akshanth R.,Pangerl Andreas,Shulman Nancy S.,Poordad Fred

Publisher

Elsevier BV

Subject

Hepatology

Reference34 articles.

1. Global distribution and prevalence of hepatitis C virus genotypes;Messina;Hepatology,2015

2. World Health Organization. Global Alert and Response (GAR) – Hepatitis C, 2015 [accessed 22.06.15].

3. Hepatitis C;Webster;Lancet,2015

4. EASL recommendations on treatment of hepatitis C 2015;J Hepatol,2015

5. AASLD/IDSA HCV guidance panel hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus;Hepatology,2015

Cited by 147 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Point-of-Care Testing for Hepatitis C in the Priority Settings of Mental Health, Prisons, and Drug and Alcohol Facilities—the PROMPt Study;Clinical Infectious Diseases;2024-03-21

2. Therapeutic Intervention of Serine Protease Inhibitors against Hepatitis C Virus;Current Medicinal Chemistry;2023-10-19

3. Clinical Practice Guidelines of the Russian Society for the Study of the Liver, the Russian Gastroenterological Association, the National Scientific Society of Infectious Disease Specialists for the Diagnosis and Treatment of Chronic Hepatitis C;Russian Journal of Gastroenterology, Hepatology, Coloproctology;2023-06-04

4. The association of donor hepatitis C virus infection with 3-year kidney transplant outcomes in the era of direct-acting antiviral medications;American Journal of Transplantation;2023-05

5. Efficacy and safety of ombitasvir/paritaprevir/ritonavir-based therapy in HCV patients with chronic kidney disease;Arab Journal of Gastroenterology;2023-02